

SETTLEMENT AGREEMENT AND MUTUAL RELEASES

This Settlement Agreement and Mutual Releases (the “Agreement”) is entered into as of January 31, 2018 (the “Effective Date”) by and between Teva Pharmaceutical Industries Ltd. (“Teva”) and Allergan plc (“Allergan”). Teva and Allergan shall be referred to collectively as the “Parties” and individually as a “Party.”

RECITALS

WHEREAS, on July 26, 2015, the Parties entered into a Master Purchase Agreement which was amended by the First Amendment to the Master Purchase Agreement dated as of June 9, 2016, the Second Amendment to the Master Purchase Agreement dated as of July 5, 2016 and the Third Amendment to the Master Purchase Agreement dated as of July 11, 2016 (the “MPA”) through which Teva acquired the Business (the “Transaction”) (capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the MPA);

WHEREAS, on August 2, 2016 (the “Closing Date”), the Transaction closed and Teva became the owner of the Business;

WHEREAS, after the Closing Date, the Parties initiated arbitration under Section 3.3 of the MPA in response to Teva’s claim for a purchase price adjustment of nearly \$1.5 billion (inclusive of all Claims by either Party under Section 3.3 of the MPA, the “Working Capital Dispute”);

WHEREAS, Teva and Allergan have made submissions to the Reporting Accountants in connection with the Working Capital Dispute (the “Submissions”);

WHEREAS, on October 30, 2017, Teva asserted several claims for indemnification under Section 12.2 of the MPA (“October 2017 Notice”), including reiterating, restating, and updating claims for indemnification made on November 30, 2016 (such claims for indemnification, together with the claims for indemnification in the October 2017 Notice, the “Teva Asserted Claims”) (the Teva Asserted Claims, collectively with any indemnification claims that Teva potentially could assert now or in the future under Section 12.2(a)(i) or Section 12.2(a)(iv) of the MPA, are referred to as the “Teva Indemnification Claims”);

WHEREAS, on November 2, 2017, Allergan asserted several claims for indemnification under Section 12.3 of the MPA (the “November 2017 Notice”), including reiterating, restating and updating claims for indemnification made on November 18, 2016 and July 13, 2017 (such claims for indemnification in the November 2017 Notice, the “Allergan Asserted Claims”) (the Allergan Asserted Claims, collectively with any indemnification claims that Allergan potentially could assert now or in the future under Section 12.3(a)(i) of the MPA, are referred to as the “Allergan Indemnification Claims”);

WHEREAS, by this Agreement, the Parties desire to resolve any and all disputes arising out of, relating to, or in any way connected to the MPA, including but not limited to the Working Capital Dispute, the Teva Indemnification Claims and the Allergan Indemnification Claims, and to avoid future disputes under the MPA; it is the Parties’ intention that, on and after the date hereof, (i) the only remedies available to Teva under the MPA are (A) indemnification under

Section 12.2(a)(ii) of the MPA for unknown breaches by Allergan of covenants that were intended to be performed by Allergan after the Closing, (B) indemnification under Section 12.2(a)(iii) of the MPA (Excluded Liability), and (C) specific enforcement of Allergan's ongoing covenants; and (ii) the only remedies available to Allergan under the MPA are (A) indemnification under Section 12.3(a)(ii) of the MPA for unknown breaches by Teva of covenants that were intended to be performed by Teva after the Closing, (B) indemnification under Section 12.3(a)(iii) (Assumed Liability) or Section 12.3(a)(iv) of the MPA (Liabilities and Claims relating to the operation of the Acquired Assets), and (C) specific enforcement of Teva's ongoing covenants;

WHEREAS, this Agreement is entered into for purposes of compromise and settlement only;

NOW, THEREFORE, in consideration of the foregoing, and the mutual promises and representations contained in this Agreement, and in exchange for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

AGREEMENT AND MUTUAL RELEASES

1. **No Admissions.** This Agreement is being entered into solely to avoid lengthy, costly and time-consuming disputes. By entering into this Agreement, no Party is admitting any liability or wrongdoing whatsoever, and each Party continues to deny any and all liability and wrongdoing. This Agreement shall not be construed as an admission by either Party as to the merits of any position adopted by the other Party.
2. **Dismissal of the Working Capital Dispute.** Within two (2) Business Days of the Effective Date, the Parties shall jointly notify the Reporting Accountants that the Parties have reached an agreement in principle for the resolution of the Working Capital Dispute and that the Reporting Accountants should cease any and all activities relating to the Working Capital Dispute pending further instructions from the Parties. Within one (1) Business Day of the payment contemplated in Section 3 hereof, the Parties shall jointly notify the Reporting Accountants that the Working Capital Dispute has been finally and fully resolved and that the arbitration is terminated. The Parties shall split evenly any external costs or expenses associated with the Working Capital Dispute, including the fees and disbursements of the Reporting Accountants, but excluding the fees and expenses of the Parties' respective advisors. Upon payment of the Settlement Amount, Allergan's obligations under Section 3.3(g) and Section 3.3(h) of the MPA shall be fully satisfied.
3. **Payment.** Within thirty (30) days following the Effective Date, Allergan shall pay Teva the sum of US \$700,000,000 (the "Settlement Amount"). The Settlement Amount shall be paid by wire transfer to the following Teva account:

MIZRAHI TEFAHOT BANK LTD IL92 0204 6100 0000 0198 781
Main Branch, Tel Aviv
Branch No: 461
Account No: 198781

Swift: MIZBILIT
Beneficiary: Teva Pharmaceutical Industries Ltd.

4. **Agreed Liabilities and Indemnification; Third Party Claim Indemnification**

Procedures. Teva agrees, on behalf of itself and each of its successors-in-interest and assigns, that it shall assume, and shall be or become responsible for (i) any Liabilities or Losses arising from the Third Party Claims listed on Exhibit A hereto, (ii) any Liabilities or Losses arising from the Third Party Claims listed on Exhibit B hereto or arising from any other Third Party Claim, in each case to the extent such Liabilities or Losses are based upon generic opioid drugs that are Products, and (iii) any Liabilities, Losses or Claims that are, directly or indirectly, jointly or severally, asserted against or imposed on Allergan, its respective Affiliates and their respective officers, directors, employees, agents, successors and permitted assigns (the "Allergan Parties") to the extent such Liabilities, Losses or Claims are based on parent or control liability or a substantially similar theory in connection with any Proceeding involving (1) a member of the Transferred Group and (2) a Product or the Business (collectively, (i), (ii) and (iii), the "Teva Agreed Liabilities"). For the avoidance of doubt, any Liabilities or Losses arising from the Third Party Claims listed on Exhibit B hereto or arising from any other Third Party Claim, in each case to the extent such Liabilities or Losses are based upon branded opioid drugs of the Retained Business that are not Products, are Excluded Liabilities under the MPA for which Teva is entitled to indemnification under Section 12.2(a)(iii) of the MPA. Teva further agrees that it will indemnify, defend and hold harmless the Allergan Parties, from, against and in respect of any and all Losses imposed on, sustained, incurred or suffered by, or asserted against, any of the Allergan Parties, whether in respect of third party claims, claims between the Parties, or otherwise, directly or indirectly relating to, arising out of, resulting from, based upon the underlying facts of, with respect to or by reason of the Teva Agreed Liabilities. Teva shall have 90 days from the Effective Date to notify Allergan that it desires to defend Allergan against any of the matters listed on Exhibit A hereto in accordance with the terms of Section 12.4 of the MPA. Unless otherwise agreed by the Parties, (i) Allergan shall be responsible for the defense of Third Party Claims involving opioid drugs to the extent such Third Party Claims are based upon branded opioid drugs of the Retained Business that are not Products and (ii) Teva shall be responsible for the defense of Third Party Claims involving opioid drugs to the extent such Third Party Claims are based upon generic opioid drugs that are Products. In the case of Third Party Claims that involve both (i) branded opioid drugs of the Retained Business that are not Products and (ii) generic opioid drugs that are Products, the Parties shall (x) each be responsible for the defense of such Third Party Claims in accordance with the immediately prior sentence and (y) cooperate with each other to enable the proper and adequate defense of such Third Party Claim. Each Party further agrees to provide the other Party by no later than February 28, 2018 a supplemental list which includes all additional known Third Party Claims based upon opioid drugs received by such Party on or before February 25, 2018 ("Supplemental Opioid Case List"), which shall be in substantially the same format as Exhibit B; any Third Party Claims appearing on Exhibit B (or the Supplemental Opioid Case List) shall be deemed to have been notified by each Party in compliance with Section 12.4 of the MPA. On or before the first Business Day of each month beginning after March 31, 2018, each Party shall provide the other Party with a list of additional Third Party Claims based upon opioid drugs that have been filed and served upon the Party on or prior to the third to last Business Day of the prior month ("Monthly Opioid

Case List”). The Monthly Opioid Case List shall be in substantially the same format as Exhibit B and the Supplemental Opioid Case List, and each Party may request a copy of a complaint listed thereon. The Parties’ respective rights and obligations pursuant to Section 12.4 of the MPA shall otherwise remain unchanged, including but not limited to the Parties’ obligations to cooperate following the date hereof to ensure the proper and adequate defense of a Third Party Claim.

5. **Mutual Releases.**

- (a) Teva, for itself and its past and present parents, subsidiaries, affiliates, directors, managers, officers, shareholders, employees, attorneys, agents, representatives, predecessors, successors and assigns, hereby fully and forever releases and discharges Allergan and its past and present parents, subsidiaries, affiliates, directors, managers, officers, shareholders, employees, attorneys, agents, representatives, predecessors, successors and assigns, from any and all claims, counterclaims, demands, damages, debts, liabilities, attorneys’ fees, actions, causes of action, obligations and demands whatsoever, whether fixed or contingent, at law or in equity, and now known or unknown (each, a “Claim”), (i) arising from or in any way relating to (A) the Working Capital Dispute, (B) the Teva Indemnification Claims (except for any Liabilities or Losses arising from the Third Party Claims listed on Exhibit B hereto or arising from any other Third Party Claim, in each case to the extent such Liabilities or Losses are based upon branded opioid drugs of the Retained Business that are not Products), (C) the Teva Agreed Liabilities, (D) any breach or alleged breach by Allergan of any representation or warranty contained in the MPA, (E) any breach or alleged breach by Allergan of any covenant in the MPA that was intended to be performed by Allergan or its Affiliates on or prior to the Closing, (F) any breach or alleged breach by Allergan prior to the date hereof of any covenant in the MPA that was intended to be performed by Allergan or its Affiliates after the Closing (an “Allergan Post-Closing, Pre-Settlement Covenant Breach”) other than any Allergan Post-Closing, Pre-Settlement Covenant Breach the material underlying facts of which are unknown to Teva as of the date hereof or (G) the historical financial statements of the Business or the Transferred Group, including any Claim that such financial statements do not comply with U.S. GAAP or any other applicable accounting standards or Laws, or (ii) for any Losses resulting from any potential Claims that are referenced in the Submissions (collectively, the “Teva Released Claims”).
- (b) Allergan, for itself and its past and present parents, subsidiaries, affiliates, directors, managers, officers, shareholders, members, employees, attorneys, agents, representatives, predecessors, successors and assigns, hereby fully and forever releases and discharges Teva and its past and present parents, subsidiaries, affiliates, directors, managers, officers, shareholders, employees, attorneys, agents, representatives, predecessors, successors and assigns, from any and all Claims (i) arising from or in any way relating to (A) the Working Capital Dispute, (B) the Direct Claims specified in the November 2017 Notice, (C) the Third Party Claims for indemnification listed on Exhibit C hereto, (D) any breach or alleged

breach by Teva of any representation or warranty contained in the MPA, (E) any breach or alleged breach by Teva of any covenant in the MPA that was intended to be performed by Teva or its Affiliates on or prior to the Closing or (F) any breach or alleged breach by Teva prior to the date hereof of any covenant in the MPA that was intended to be performed by Teva or its Affiliates after the Closing (a “Teva Post-Closing, Pre-Settlement Covenant Breach”) other than any Teva Post-Closing, Pre-Settlement Covenant Breach the material underlying facts of which are unknown to Allergan as of the date hereof, or (ii) for any Losses resulting from any potential Claims that are referenced in the Submissions (collectively, the “Allergan Released Claims”).

- (c) Except as provided herein, (i) Teva shall continue to have rights to indemnification under Section 12.2(a)(ii) and Section 12.2(a)(iii) of the MPA; and (ii) Allergan shall continue to have rights to indemnification under Section 12.3(a)(ii), Section 12.3(a)(iii) and Section 12.3(a)(iv) of the MPA. For the avoidance of doubt, (i) Teva shall be prohibited from asserting any of the Teva Released Claims as Claims under Section 12.2(a)(iii) of the MPA, (ii) Allergan shall be prohibited from asserting any of the Allergan Released Claims as Claims under Section 12.3(a)(iii) or Section 12.3(a)(iv) of the MPA and (iii) the rights and obligations of the Parties under Section 9.1 of the MPA shall remain in effect.
- (d) The Parties acknowledge that the releases in this Agreement may include a release of claims, counterclaims, demands, damages, debts, liabilities, attorneys’ fees, actions, causes of action, obligations and demands whatsoever, whether fixed or contingent, at law or in equity that are unknown or unsuspected. The Parties hereby waive any common law or statutory doctrine or provision that limits the effect of a release of unknown or unsuspected claims, counterclaims, demands, damages, debts, liabilities, attorneys’ fees, actions, causes of action, obligations and demands whatsoever, whether fixed or contingent, at law or in equity. The releases in this Agreement are to be interpreted as broadly as the law allows.
- (e) Teva represents and warrants to Allergan that no Buyer Indemnified Party has received any Third Party Claim against a Buyer Indemnified Party other than (i) the Teva Indemnification Claims and (ii) any Third Party Claims based upon any branded or generic opioid drugs.
- (f) Allergan represents and warrants to Teva that no Seller Indemnified Party has received any Third Party Claim against a Seller Indemnified Party other than (i) the Allergan Indemnification Claims and (ii) the Third Party Claims listed on Exhibit A or Exhibit B hereto and any Third Party Claims based upon any branded or generic opioid drugs.

6. Covenant Not to Sue and Agreement to Indemnify.

- (a) Teva agrees, on behalf of itself and each of its current and former directors, officers, employees, representatives, agents, controlling entities or persons, predecessors or successors-in-interest and assigns, (i) that it will neither initiate

nor continue any claims, suits, actions, arbitrations or proceedings that seek any relief based upon the Teva Released Claims or the Teva Agreed Liabilities and (ii) that it will not assign or otherwise transfer the Teva Released Claims to any party. Teva further agrees that it will indemnify Allergan for any and all costs, charges or expenses, including but not limited to reasonable attorneys' fees, incurred in connection with any breach of this Section 6(a).

- (b) Allergan agrees, on behalf of itself and each of its current and former directors, officers, employees, representatives, agents, controlling entities or persons, predecessors or successors-in-interest and assigns, (i) that it will neither initiate nor continue any claims, suits, actions, arbitrations or proceedings that seek any relief based upon the Allergan Released Claims and (ii) that it will not assign or otherwise transfer the Allergan Released Claims to any party. Allergan further agrees that it will indemnify Teva for any and all costs, charges or expenses, including but not limited to reasonable attorneys' fees, incurred in connection with any breach of this Section 6(b).

7. **Representations and Warranties of the Parties.** The Parties represent and warrant to one another that:

- (a) Such Party has the legal right, capacity and authority to enter into this Agreement;
- (b) Such Party has taken all necessary corporate and legal actions, as applicable, to duly approve the making and performance of this Agreement;
- (c) This Agreement has been validly executed and delivered by such Party and constitutes its valid and binding obligation, enforceable against the Party in accordance with the terms hereof;
- (d) Neither the execution nor performance of this Agreement by such Party constitutes or will constitute a violation or breach of such Party's charter or bylaws (or comparable documents, as applicable);
- (e) Neither the execution nor the performance of this Agreement will constitute a violation or breach of any law, order, injunction, judgment, statute or regulation applicable to such Party or constitutes or will constitute a material default (or would, with the passage of time or the giving of notice, or both, constitute such a default) under any material contract, agreement or other instrument to which such Party is a party or by which it is bound;
- (f) Such Party has not relied upon any document, statement, representation, promise, inducement, understanding or information made or provided by any other Party or its representatives except as expressly set forth in this Agreement, and such Party has relied solely upon its own due diligence and independent judgment concerning this Agreement and the Party's decision to enter into this Agreement;
- (g) Such Party has read this Agreement and fully understands all of its terms, covenants, conditions, provisions and obligations and such Party believes that this

Agreement is a fair, just and reasonable resolution of the Working Capital Dispute, the Teva Indemnification Claims and the Allergan Indemnification Claims;

- (h) Such Party specifically acknowledges that this Agreement shall not be subject to any claim of mistake of fact, that it expresses a full and complete settlement between the Parties, and that regardless of the adequacy or inadequacy of the consideration described herein, this Agreement is intended to be a final and complete settlement of claims and obligations between the Parties described herein as covered by this Agreement; and
 - (i) Such Party has not assigned or transferred any Claim or interest in any claim that is the subject of the releases in this Agreement.
8. **Multiple Counterparts.** This Agreement: (i) may be executed in one or more counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument and shall be binding upon the person or entity executing the same; and (ii) may be executed by a signature page delivered by facsimile or email, in which case the person or entity so executing this Agreement shall promptly thereafter deliver its originally executed signature page (but the failure to deliver an original shall not affect the binding nature of such person's or entity's signature).
9. **Governing Law.** This Agreement shall be governed by the laws of the State of New York without regard to its conflict of laws provisions.
10. **Dispute Resolution.** Any dispute, controversy or claim relating to the interpretation or construction of Sections 4 or 5 of this Agreement, or to the determination of whether a claim for indemnification made by a Party under Sections 12.2 or 12.3 of the MPA is, in fact, subject to indemnification under the MPA, shall be finally resolved by arbitration in accordance with the International Institute for Conflict Prevention and Resolution ("CPR") Rules for Non-Administered Arbitration ("Rules") as in effect on the date of the Agreement, or such other rules and procedures as the Parties may agree. The arbitration will be conducted before a panel of three arbitrators, to be selected in accordance with the screened selection process provided in the Rules. The place of arbitration shall be New York, New York. The language of the arbitration shall be English. Except as otherwise agreed by the Parties, the arbitrators shall issue an award within ninety (90) days of the filing of the notice of intention to arbitrate, and the arbitrators shall agree to comply with this schedule before accepting appointment. Any claims for indemnification sought by Allergan involving allegations against the Transferred Group that relate to Claims based upon (i) contracts for services related to generic drugs that are Products or (ii) alleged or actual violations of competition or antitrust Laws in the generic drug market involving Products (other than any such violation of competition or antitrust Laws relating to any litigation settlement agreement between Allergan and Teva (or between their respective Affiliates)), shall be subject to a rebuttable presumption by the arbitrators that such claims are subject to indemnification by Teva under the MPA. Any claims for indemnification sought by Teva involving allegations against the Transferred Group that relate to Claims based upon (i) contracts for services related to branded drugs of the Retained Business that are not Products or (ii) alleged or

actual violations of competition or antitrust Laws in the branded drug market involving products of the Retained Business that are not Products (other than any such violation of competition or antitrust Laws relating to any litigation settlement agreement between Allergan and Teva (or between their respective Affiliates)), shall be subject to a rebuttable presumption by the arbitrators that such claims are subject to indemnification by Allergan under the MPA. In the event the arbitrators determine that the rebuttable presumption is inapplicable, the arbitrators will then proceed to determine whether the claim for indemnification is subject to indemnification under the MPA. Any award issued by the arbitrators shall be final, binding and conclusive on the Parties hereto and shall constitute an arbitral award upon which a judgment may be entered in any court having jurisdiction thereof. The prevailing party in any arbitration conducted under this provision will be entitled to an award of all fees, costs and expenses of the arbitrators and the arbitration (including, for the avoidance of doubt, reasonable attorneys' fees).

11. **No Effect on Manufacturing Agreements.** Nothing in this Agreement shall modify or in any way affect the parties' rights and obligations under any manufacturing or supply agreements between Allergan and Teva (or between their respective Affiliates).
12. **Kadian Agreement.** Teva shall, and shall cause its Controlled Affiliates to, (i) cooperate with Allergan to assign the Asset Purchase Agreement, dated December 17, 2008, by and between Actavis Elizabeth, LLC and King Pharmaceuticals, Inc. (the "Kadian Agreement") to Allergan or its Affiliate, such assignment to be effectuated by an agreement mutually satisfactory to Teva and Allergan, and (ii) prior to the assignment of the Kadian Agreement to Allergan or its Affiliate, cooperate with Allergan to provide Allergan with the benefits of the Kadian Agreement, including cooperation in asserting any indemnification rights of Actavis Elizabeth, LLC (or its successors and assigns) under the Kadian Agreement. Following the assignment of the Kadian Agreement to Allergan or its Affiliate, Allergan shall, and shall cause its Controlled Affiliates to, cooperate with Teva to provide Teva with the benefits of the Kadian Agreement that relate to the authorized generic of Kadian®, including cooperation in asserting any indemnification rights of Teva or its Controlled Affiliates under the Kadian Agreement with respect to any Liabilities or Losses to the extent such Liabilities or Losses are based upon or related to the authorized generic of Kadian®.
13. **No Modification.** This Agreement may only be modified or amended by a writing dated after the date hereof and signed by each of the Parties.
14. **Construction.**
 - (a) This Agreement shall be construed so that the word "including" means "including without limitation;" and the singular shall include the plural and vice versa.
 - (b) For the avoidance of doubt, "Products" as used in this Agreement shall exclude any products that are Excluded Assets.
 - (c) Titles or headings contained in this Agreement are included only for ease of reference and will have no substantive effect.

- (d) None of the Parties will be entitled to have any language contained in this Agreement construed against another because of the identity of the drafter.
15. **Confidentiality**. Neither of the Parties hereto shall issue, make or cause to be made any disclosures regarding the terms of this Agreement without the written consent of the other Party, except that the Parties (i) may disclose the terms of this Agreement to attorneys, accountants and other advisors retained by the Party; (ii) may make such disclosures as may be required by applicable laws or regulations, provided that the disclosing Party notifies the other Party in writing of any such requirement and the intended disclosure at least two (2) Business Days in advance of any such disclosure; and (iii) may disclose that they entered into a “Settlement Agreement” without disclosing its terms. Either of the Parties may disclose the terms and conditions of this Agreement if such Party receives a subpoena or other process or order to produce this Agreement, provided that such Party shall, prior to any disclosure to any third party, promptly notify the other Parties to this Agreement so that each Party has a reasonable opportunity to respond to such subpoena, process or order. The Party receiving a subpoena, process or order shall (in the first instance) take no action contrary to the confidentiality provisions set forth above, and shall make reasonable efforts to respond only subject to the confidentiality designation available under a protective order in litigation. The Party objecting shall have the burden of defending against such subpoena, process or order. The Party receiving the subpoena, process or order shall be entitled to comply with it, except to the extent that any other Party is successful in obtaining an order modifying or quashing it.
16. **Entire Agreement**. This Agreement constitutes the full and entire understanding and agreement among the Parties with regard to the subject hereof and supersedes any prior negotiations, representations or agreements, written or oral, with respect to such subject matter; provided, however, that nothing herein shall amend, modify, or supersede the Tax Settlement and Resolution Agreement dated October 15, 2017, which the Parties intend to remain in full force and effect.
17. **Severability**. If any term or provision of this Agreement is held to be invalid, illegal or contrary to public policy, such term or provision shall be modified to the extent necessary to be valid and enforceable and shall be enforced as modified; provided, however, that if no modification is possible such provision shall be deemed stricken from this Agreement. In any case, the remaining provisions of this Agreement shall not be affected thereby.
18. **No Waiver**. Any waiver of any Party’s rights under this Agreement is only effective if in writing signed by the Party to be charged or its duly authorized representative, and any such waiver shall only be effective for the specific matter waived and shall not be deemed to apply to any other conduct, provision or other matter.
19. **No Assignment**. The Parties agree that they have not, and will not, sell, transfer or assign, or purport to sell, transfer or assign, any Claim or interest in any claim that is the subject of the releases in this Agreement.
20. **Allocation of Global Purchase Price**. Within thirty (30) days following the Effective Date, Allergan shall deliver to Teva the final allocation of the Global Purchase Price (which, for the avoidance of doubt, shall be reduced by the entire amount of the Settlement Payment)

among the Acquired Assets (the "Final PPA"). Teva agrees to treat the Final PPA as the Global Purchase Price Allocation in accordance with the MPA.

21. **Notices.** All notices and other communications hereunder shall be in writing, shall be sent by Federal Express or other expedited courier service, and shall be deemed effective and duly given upon delivery to the other Party at the following addresses or to such other addresses as the Parties may notify one another of in accordance with the provision of this Section:

If to Teva:

Teva Pharmaceutical Industries Ltd.
5 Basel Street
Petach Tikva 4951033
Israel
Attention: Chief Legal Officer
Facsimile: +11 972 3 926-7896

With a copy (which does not constitute notice) to:

Vinson & Elkins LLP
666 Fifth Avenue
New York, NY 10103
Attention: Ari Berman
Facsimile: +1 (917) 849-5368

If to Allergan:

Allergan PLC
Clonsaugh Business and Technology Park
Coolock
Dublin, D17 E400
Ireland
Attention: Chief Legal Officer and Secretary
Facsimile: +1 (862) 261-8223

With copies to (which shall not constitute notice):

Allergan plc
5 Giralda Farms
Madison, New Jersey 07940
Attention: Chief Legal Officer and Secretary
Facsimile: +1 (862) 261-8223

and:

Latham & Watkins LLP
885 Third Avenue
New York, NY 10022-4834


Attention: Charles K. Ruck
R. Scott Shean
Facsimile: +1 (212) 751-4864

22. **Independent Legal Advice.** This Agreement was negotiated between the Parties at arm's length. Teva and Allergan acknowledge that they have been advised by their own independently selected counsel and other advisors in connection with this Agreement. Teva and Allergan further acknowledge that they enter into this Agreement solely on the basis of advice from independently selected counsel and on the basis of their own independent investigation of all of the facts, laws and circumstances material to this Agreement or any provision hereof, and not in any manner or to any degree based upon any statement or omission by any other party hereto or its counsel. As such, Teva and Allergan agree that they shall have no basis to challenge, set aside or void this Agreement on grounds of fraud, fraudulent inducement or related legal theories.

[SIGNATURE PAGES FOLLOW]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed in their respective names by their duly authorized representatives as of the date and year written below.

TEVA PHARMACEUTICAL INDUSTRIES, ALLERGAN PLC
LTD.



Name: Michael McClellan

Date: January 31, 2018

Name: _____

Date: _____

TEVA PHARMACEUTICAL INDUSTRIES,
LTD.


Name: Sharon Horvath

Date: January 31, 2018

LEGAL
FILES

SIGNATURE PAGE TO SETTLEMENT AGREEMENT AND MUTUAL RELEASES

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

ALLERGAN_MDL_SUPP_0000143

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

ALLERGAN_MDL_01396698

P-16056 _ 00012


IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed in their respective names by their duly authorized representatives as of the date and year written below.

TEVA PHARMACEUTICAL INDUSTRIES,
LTD.

Name: _____

Date: _____

ALLERGAN PLC



Name: *R. Robert D. Bailey*
Chief Legal Officer & Corporate Secretary

Date: January 31, 2018

TEVA PHARMACEUTICAL INDUSTRIES,
LTD.

Name: _____

Date: _____

Exhibit A

- U.K. Competition and Markets Authority investigations relating to hydrocortisone tablets and any related Claims, including any related Claims by the National Health Service
- U.K. Competition and Markets Authority investigations relating to carbimazole and any related Claims, including any related Claims by the National Health Service
- U.K. Competition and Markets Authority investigations relating to nortriptyline and any related Claims, including any related Claims by the National Health Service
- U.K. Competition and Markets Authority investigations relating to fludrocortisone acetate and any related Claims, including any related Claims by the National Health Service
- U.K. Competition and Markets Authority investigations relating to dexamethasone and any related Claims, including any related Claims by the National Health Service
- U.K. Competition and Markets Authority investigations relating to amantadine and any related Claims, including any related Claims by the National Health Service
- *Lanoel v. Teva Pharmaceutical Industries Ltd., et al.*, Derivative Action No. 2453-03-17 (Tel Aviv)
- *Federal Trade Commission v. Allergan plc, et al.*, Case No. 3: 17-cv-00312 (N.D. Cal.)
- *Floyd v. Feygin, et al.*, Case No. 507458/2017 (N.Y. Sup. Ct.)
- *State of California v. Watson Laboratories, Inc., et al.*, Case No. 3:17-CV-00562 (N.D. Cal.)
- *Benta SAL v. Actavis (MEEA) FZE, et al.* (Lebanon)

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

ALLERGAN_MDL_SUPP_00000145

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

ALLERGAN_MDL_01396700

P-16056 _ 00015

Exhibit B

Case Name	Case Number	Where Case Was Filed
Adams County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00894	Southern District of Ohio
American Federation of State, County, and Municipal Employees District Council 37 Health & Security Plan, individually and on behalf of all those similarly situated v. Purdue Pharma, L.P.	1:17-cv-02585	Northern District of Ohio
Amite County, Mississippi v. AmerisourceBergen Drug Corporation et al.	5:18-cv-00009-DCB-MTP	Southern District of Mississippi
Ashland County Board of County Commissioners v. AmerisourceBergen Drug Corporation et al.	17-cv-02569	Northern District of Ohio
Baldwin County, Alabama v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00010	Southern District of Alabama
Baptist Hospital, Inc. and Jay Hospital, Inc. v. McKesson Corp., et al.	3:17-cv-00816	Northern District of Florida
Belmont County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00663	Southern District of Ohio
Benton County, Mississippi v. AmerisourceBergen Drug Corporation et al.	3:18-cv-00007-MPM-RP	Northern District of Mississippi
Berkely County Council v. Purdue Pharmaceutical Products, LP, et al.	3:17-cv-00143	Northern District of West Virginia
Board of County Commissioners of Sedgwick County, Kansas v. AmerisourceBergen Drug Corp. et al.	6:17-cv-01313 18-op-45025 (MDL)	District of Kansas

Case Name	Case Number	Where Case Was Filed
Bossier Parish v. AmerisourceBergen Drug Corp. et al.	3:17-cv-01815	Middle District of Louisiana
Brooke County Commission et al. v. Purdue Pharma, L.P. et al	17-c-258 through 255	Circuit Court of Marshall County, West Virginia
Brooke County Commission; Hancock County Commission; Harrison County Commission; Lewis County Commission; Marshall County Commission; Ohio County Commission; Tyler County Commission; And Wetzel County Commission, v. Purdue Pharma L.P. et al.	5:18-cv-00009-JPB	Northern District of West Virginia
Brown County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00664	Southern District of Ohio
Buchanan County, Missouri v. AmerisourceBergen Drug Corporation et al.	5:17-cv-06141	Western District of Missouri
Buncombe County v. AmerisourceBergen Drug Corporation et al.	1:17-cv-00310	Western District of North Carolina
Butler County Board of Commissioners v. Purdue Pharma, LP et al.	2:17-cv-01024	Southern District of Ohio
Campbell County, Tennessee v. AmerisourceBergen Drug Corporation et al.	3:18-cv-00006	Eastern District of Tennessee
Catawba County, North Carolina v. AmerisourceBergen Drug Corporation et al.	5:18-cv-00007	Western District of North Carolina
Cecil County, Maryland v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00063-GLR	District of Maryland

Case Name	Case Number	Where Case Was Filed
City of Alexandria, City of Elwood and Madison County v. Purdue Pharma L.P. et al.	1:18-cv-00123-TWP-MJD	Southern District of Indiana
City of Baton Rouge, parish of East Baton Rouge, Louisiana v. AmerisourceBergen Drug Corporation	3:18-cv-00047	Middle District of Louisiana
City of Birmingham v. Purdue Pharma LP et al.	2:17-cv-01360 17-op-45008 (MDL)	Northern District of Alabama
City of Chicago v. Purdue Pharma	1-14-cv-04361 17-op-45169 (MDL)	Northern District of Illinois
City of Chicago v. Purdue Pharma LP et al.	14-cv-60604	Northern District of Illinois
City of Cincinnati, Ohio v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00713	Southern District of Ohio
City of Connersville and Fayette County v. Purdue Pharma L.P. et al.	1:18-cv-00175-WTL-TAB	Southern District of Indiana
City of Dayton, Ohio v. Purdue	3:17-cv-00229	Southern District of Ohio (Originally in Montgomery County Court of Common Pleas)
City of Detroit, Michigan, a municipal corporation v. Purdue Pharma, L.P. et al.	2:17-cv-14075	Eastern District of Michigan
City of Escanaba, Michigan, a municipal corporation v. Purdue Pharma, L.P. et al.	2:17-cv-00208	Western District of Michigan

Case Name	Case Number	Where Case Was Filed
City of Fort Payne, Alabama, a Municipal Corporation v. AmerisourceBergen Drug Corporation et al.	4:17-cv-01877 17-op-45079 (MDL)	Northern District of Alabama
City of Gadsden, Etowah County, and Todd Entrekin, Sheriff of Etowah County, Alabama v. Purdue Pharma LP et al.	4:17-cv-01800 17-op-45101 (MDL)	Northern District of Alabama
City of Greenfield, aka Town of Greenfield v. AmerisourceBergen Drug Corporation et al.	3:17-cv-30175	District of Massachusetts
City of Greenville, Alabama v. Purdue Pharma L.P. et al.	2:17-cv-00836	Middle District of Alabama
City of Greenwood, Indiana v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00047	Southern District of Indiana
City of Hammond v. Purdue Pharma LP et al.	2:17-cv-00431	Southern District of Indiana
City of Indianapolis and Marion County v. Purdue Pharma, L.P. et al.	1:17-cv-04321 17-op-45091 (MDL)	Southern District of Indiana
City of Jacksonville v. AmerisourceBergen Drug Corporation et al.	7:18-cv-00002	Eastern District of North Carolina
City of Kokomo, Indiana v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00060-JMS-MJD	Southern District of Indiana
City of Lafayette v. Purdue Pharma LP, et al.	4:17-cv-00091	Northern District of Indiana

Case Name	Case Number	Where Case Was Filed
City of Lansing, Michigan, a municipal corporation v. Purdue Pharma, L.P. et al.	1:17-cv-01114	Western District of Michigan
City of Lorain, Ohio v. Purdue	1:17-cv-1639	Northern District of Ohio (originally in Lorain County Court of Common Pleas)
City of Manchester v. Purdue Pharma et al.	1:17-cv-00507 (originally 216-2017-CV-00649)	District of New Hampshire (originally in Hillsborough, SS Northern District until removed 10/19/2017)
City of Methuen v. AmerisourceBergen Drug Corporation et al.	1:18-cv-10035	District of Massachusetts
City of New Castle v. Purdue Pharma, LP et al.	1:17-cv-04591 18-op-45016 (MDL)	Southern District of Indiana
City of Noblesville, Indiana v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00048	Southern District of Indiana
City of Opp, Alabama, a municipal corporation v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00840 18-op-45011 (MDL)	Middle District of Alabama
City of Parma v. Purdue Pharma et al.	1:17-cv-01872	Northern District of Ohio (originally in Cuyahoga County Court of Common Pleas until 9/6/2017)
City of Philadelphia v. Allergan plc et al.	2718	Court of Common Pleas of Philadelphia County
City of Revere v. AmerisourceBergen Drug Corporation et al.	1:18-cv-10124	District of Massachusetts

Case Name	Case Number	Where Case Was Filed
City of Seattle v. Purdue Pharma LP et al.	17-2-25505-0 / 17-2-25504-1	Superior Court of the State of Washington in King County
City of Shreveport v. Purdue Pharma, L.P. et al.	605608	1st Judicial District for the Parish of Caddo
City of Woburn v. AmerisourceBergen Drug Corporation et al.	1:18-cv-10032	District of Massachusetts
Claiborne County, Mississippi v. Purdue Pharma L.P. et al.	5:17-cv-00150	Southern District of Mississippi
Clark County v. Purdue Pharma, L.P. et al.	A-17-765828-C	District court of Clark County, Nevada
Clermont County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00662	Southern District of Ohio
City of Portsmouth v. Amerisource Bergen Corp. et al.	2-17-cv-00723	Southern District of Ohio
Columbia County v. Purdue Pharma, LP et al.	4:17-cv-02067	Middle District of Pennsylvania
Columbiana County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00883	Southern District of Ohio
Coshocton County Board of County Commissioners v. AmerisourceBergen Drug Corporation et al.	2:17-cv-01105	Southern District of Ohio

Case Name	Case Number	Where Case Was Filed
Count of Grand Traverse, Michigan v. Purdue Pharma, L.P. et al.	1:17-cv-01115	Western District of Michigan
Count of Macomb, Michigan v. Purdue Pharma, L.P. et al.	4:17-cv-14077	Eastern District of Michigan
Count of Saginaw, Michigan v. Purdue Pharma, L.P. et al.	1:17-cv-14076	Eastern District of Michigan
County of Armstrong v. Purdue Pharma LP et al.		Armstrong Court of Common Pleas
County of Beaver v. Purdue Pharma LP et al.	11326-2017	Beaver Court of Common Pleas
County of Bowie v. Purdue Pharma, LP et al.	5:17-cv-00168	U.S. District Court Eastern District of Texas
County of Cambria v. Purdue Pharma LP et al.	2017-04131	Cambria Court of Common Pleas
County of Camp v. Purdue Pharma L.P. et al.	2:18-cv-00002-JRG	Eastern District of Texas
County of Cascade v. Purdue Pharma L.P. et al.	4:17-cv-00130	District of Montana
County of Cherokee v. Purdue Pharma, L.P. et al.	6:17-cv-00659	Eastern District of Texas

Case Name	Case Number	Where Case Was Filed
County of Chippewa, Michigan v. Purdue Pharma, L.P. et al.	2:17-cv-00206	Western District of Michigan
County of Crawford, Michigan v. Purdue Pharma L.P. et al.	1:18-cv-10077-JEL-PTM	Eastern District of Michigan
County of Dallas v. Purdue Pharma L.P. et al.	DC-18-00290	116th District Court
County of Delta, Michigan v. Purdue Pharma, L.P. et al.	2:17-cv-00207	Western District of Michigan
County of Falls v. Purdue Pharma L.P. et al.	CV40015	82nd District Court, TX
County of Fayette v. Purdue Pharma L.P. et al.	2017-02676	Court of Common Pleas of Fayette County, Pennsylvania
County of Franklin v. Purdue Pharma, L.P. et al.	5:18-cv-00002	Eastern District of Texas
County of Franklin v. Purdue Pharma L.P. et al.	5:18-cv-00002	Eastern District of Texas
County of Fulton v. Purdue Pharma L.P. et al.	17EV005007	State Court of Fulton County
County of Genesee, Michigan v. Purdue Pharma, L.P. et al.	4:17-cv-14074	Eastern District of Michigan
County of Greene v. Purdue Pharma LP et al.	AD-791-2017	Greene Court of Common Pleas

Case Name	Case Number	Where Case Was Filed
County of Harrison v. Purdue Pharma, L.P. et al.	2:17-cv-00748	Eastern District of Texas
County of Hopkins v. Purdue Pharma, LP et al.	CV43486	62nd Judicial District Court
County of Jones v. Purdue Pharma L.P. et al.	1:18-cv-00003-C	Northern District of Texas
County of Lackawanna v. Purdue Pharma LP et al.	17-cv-5156	Lackawanna Court of Common Pleas
County of Lamar v. Purdue Pharma, L.P. et al.	4:17-cv-00814	Eastern District of Texas
County of Lawrence v. Purdue Pharma LP, et al.	1180-17	Lawrence County Court of Common Pleas
County of Leelanau, Michigan v. Purdue Pharma L.P. et al.	1:18-cv-00030	Western District of Michigan
County of Leon v. Purdue Pharma, LP et al.	6:17-cv-00318	Western District of Texas
County of Manistee, Michigan v. Purdue Pharma L.P. et al.	1:18-cv-00033	Western District of Michigan
County of Marquette, Michigan v. Purdue Pharma L.P. et al.	2:18-cv-00001	Western District of Michigan
County of Mason, Michigan v. Purdue Pharma L.P. et al.	1:18-cv-00032	Western District of Michigan
County of Mitchell v. Purdue Pharma L.P. et al.	1:17-cv-00197	Northern District of Texas
County of Mora v. Purdue Pharm et al.	1:17-cv-01044 (originally D-430-CV-2017-00067)	District of New Mexico (originally in State of NM Fourth Judicial District Court until removed)

Case Name	Case Number	Where Case Was Filed
		10/16/2017)
County of Morris v. Purdue Pharma, L.P., et al.	2:17-cv-00725	Eastern District of Texas
County of Multnomah v. Purdue Pharma L.P. et al	17CV33413	Circuit Court of the State of Oregon
County of Niagara v. Purdue Pharma LP et al.	E162958/2017	Supreme Court Niagara County
County of Nolan v. Purdue Pharma L.P. et al.	1:17-cv-00196	Northern District of Texas
County of Onondaga, New York v. Purdue Pharma, L.P.	5:18-CV-0100	Northern District of New York
County of Osceola v. Purdue Pharma L.P. et al.	64431661	Circuit Court of the Ninth Judicial Circuit and for Osceola County, Florida
County of Pike v. Purdue Pharma LP, et al.	17-CV-0128	Circuit Court of Pike County, Kentucky
County of Polk v. Purdue Pharma L.P. et al.	9:17-cv-00213	Eastern District of Texas
County of Red River v. Purdue Pharma, L.P., et al.	5:17-cv-00185	Eastern District of Texas
County of Roscommon, Michigan v. Purdue Pharma L.P. et al.	1:18-cv-10078-TLL- PTM	Eastern District of Michigan

Case Name	Case Number	Where Case Was Filed
County of Rusk v. Purdue Pharma, L.P. et al.	6:17-cv-00634	Eastern District of Texas
County of Smith, Texas v Purdue Pharma L.P. et al.	6:17-cv-00699	Eastern District of Texas
County of Throckmorton v. Purdue Pharma L.P. et al.	11125	62nd Judicial District Court
County of Throckmorton v. Purdue Pharma L.P. et al.	1:18-cv-00004-C	Northern District of Texas
County of Titus v. Purdue Pharma, L.P. et al.	5:17-cv-00189	Eastern District of Texas
County of Upshur v. Purdue Pharma LP et.al.	2:17-cv-00672	U.S. District Court Eastern District of Texas
County of Van Zandt v. Purdue Pharma L.P. et al.	17-00302	294th Judicial District Court
Crawford County Board of County Commissioners v. AmerisourceBergen Drug Corporation et al.	2:17-cv-00975	Southern District of Ohio
Darke County Board of County Commissioners	2:17-cv-01064	Southern District of Ohio
DeKalb County, Georgia v. Purdue Pharma, L.P. et al.	17CV12677	Superior Court of DeKalb County
Drew Memorial Hospital, Inc. v. Purdue Pharma L.P. et al.	CV-17-221-3	Circuit Court of Drew County, Arkansas
Eastern Band of Cherokee Indians v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00004	Western District of North Carolina
Erie County Board of County Commissioners v. AmerisourceBergen Corp et al.	2:17-cv-00918	Southern District of Ohio

Case Name	Case Number	Where Case Was Filed
Fairfield County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-01012	Southern District of Ohio
Flandreau Santee Sioux Tribe, Rosebud Sioux Tribe, and Sisseton-Wahpeton Oyate v. Purdue Pharma L.P. et al.	4:18-cv-04003-KES	District of South Dakota
Forrest County, Mississippi v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00009-KS-MTP	Southern District of Mississippi
Gallia County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00768	Southern District of Ohio
Greene County, Tennessee v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00002	Eastern District of Tennessee
Guernsey County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00886	Southern District of Ohio
Hancock County, Tennessee v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00010	Eastern District of Tennessee
Haywood County, Tennessee v. AmerisourceBergen Drug Corporation et al.	2:18-cv-02016	Western District of Tennessee
Hocking County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00769	Southern District of Ohio
Houston County, Alabama v. Purdue Pharma L.P. et al.	1:17-cv-00838	Middle District of Alabama
Humphreys County, Mississippi v. Purdue Pharma, LP et al.	4:17-cv-00190	Northern District of Mississippi

Case Name	Case Number	Where Case Was Filed
Huron County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00891	Southern District of Ohio
IBEW local 38 Health and Welfare Fund, on behalf of itself and all others similarly situated v. Purdue Pharma et al.	1:17-cv-02171 18-op-45069 (MDL)	Northern District of Ohio
Teamsters Local 493 Health Services and Insurance Plan v. Purdue Pharma, L.P. et al.	3:17-cv-02092 18-op-45074 (MDL)	District of Connecticut
IBEW Local 671 Health Services and Insurance Plan v. Purdue Pharma, L.P. et al.	3:17-cv-02093	District of Connecticut
Teamsters Local 677 Health Services and Insurance Plan v. Purdue Pharma, L.P. et al.	3:17-cv-02094 18-op-45071 (MDL)	District of Connecticut
IBEW Local 90 Benefits Plan v. Purdue Pharma, L.P. et al.	3:17-cv-02095	District of Connecticut
IN RE: National Prescription Opiate Litigation	MDL 2804	US Judicial Panel on Multidistrict Litigation
J. Paul Jones Hospital, a Non-Profit Alabama Corporation v. McKesson Corporation et al.	2:18-cv-00029	Southern District of Alabama
Jackson County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00680	Southern District of Ohio
Jefferson County Council v. Purdue Pharmaceutical Products, LP, et al.	3:17-cv-00144	Northern District of West Virginia
Jefferson Davis County, Mississippi v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00200	Southern District of Mississippi

Case Name	Case Number	Where Case Was Filed
Jennings County vs. Purdue Pharma L.P. et al	4:18-cv-00006-RLY-TAB	Southern District of Indiana
Johnson County, Tennessee v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00003	Eastern District of Tennessee
Laborers 17 Health Benefit Fund v. Purdue Pharma, L.P. et al.	1:17-cv-09877	Southern District of New York
Lake County v. Purdue Pharma L.P. et al.	2:18-cv-00024	Northern District of Indiana
Lewis v. Purdue Pharma L.P. et al	5:17-cv-05118 17-op-45076 (MDL)	Western District of Arkansas
Lexington-Fayette Urban County Government v. AmerisourceBergen Drug Corporation et al.	5:17-cv-00442	Eastern District of Kentucky
Licking County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00904	Southern District of Ohio
Logan County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-01097	Southern District of Ohio
Louisiana Department of Health v. Purdue Pharma et al.	C 661 638 / U61638	East Baton Rouge 19th Judicial District Court
Louisiana Health Service & Indemnity Company d/b/a Blue Cross Blue Shield of Louisiana, and HMO Louisiana, Inc. v. Purdue Pharma, LP et al.	663226	East Baton Rouge 19th Judicial District Court
Louisville/Jefferson County Metro Government v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00508	Western District of Kentucky

Case Name	Case Number	Where Case Was Filed
Luzerne County v. Purdue Pharma, LP et al.	3:17-cv-02043	Middle District of Pennsylvania
Marion County, Mississippi v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00202	Southern District of Mississippi
Marshall County v. Purdue Pharma, L.P. et al.	3:18-cv-00046	Northern District of Indiana
Metropolitan Government of Nashville and Davidson County, Tennessee v. Purdue Pharma L.P. et al.	3:17-cv-01605	Middle District of Tennessee
Mobile County Emergency Medical Services System Rescue Squad, Inc., A nonprofit corporation; v. AmerisourceBergen Drug Corporation et al.	1:18-cv-00016-B	Southern District of Alabama
Morrow County Board of Commissioners v. Purdue Pharma L.P. et al.	2:17-cv-01126	Eastern District of Ohio
Mower County v. Purdue Pharma LP, et al.	0:17-cv-05263	District of Minnesota
MSP Recovery Claims, Series LLC v. Purdue Pharma, L.P.	1:18-cv-00040	Northern District of Ohio
MSPA Claims I, LLC; MAO-MSO Recovery II, LLC; and MSP Recovery Claims, Series LLC; v. Purdue Pharma L.P. et al.	1:18-cv-00130	Northern District of Ohio
Municipality of Guayama, Puerto Rico v. Purdue Pharma L.P. et al.	3:17-cv-02356	District of Puerto Rico
Municipality of Guayanilla, Puerto Rico v. Purdue Pharma L.P. et al.	3:17-cv-02364	District of Puerto Rico

Case Name	Case Number	Where Case Was Filed
Municipality of Loiza, Puerto Rico v. Purdue Pharma L.P. et al.	3:17-cv-02371	District of Puerto Rico
Municipality of Sabana Grande and Municipality of Cayey on behalf of themselves and others similarly situated v. Purdue Pharma L.P. et al.	3:17-cv-02380	District of Puerto Rico
Muskingum County Board of County Commissioners v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00040-ALM-KAJ	Southern District of Ohio
New Hanover County v. AmerisourceBergen Drug Corp. et al.	7:17-cv-00241	Eastern District of North Carolina
Oklahoma State v Purdue Pharma et al.	CJ-2017-816	Cleveland County District Court
Onslow County v. AmerisourceBergen Drug Corporation et al.	7:18-cv-00001	Eastern District of North Carolina
Ottawa County Board of County Commissioners v. AmerisourceBergen Drug Corporation et al.	3:17-cv-02570	Northern District of Ohio
Pike County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00696	Southern District of Ohio
Ramsey County, Minnesota v. Purdue Pharma L.P. et al.	0:17-cv-05285	District of Minnesota
Regina Hapgood, Individually and on behalf of the Estate of Richard Coelho v. Purdue Pharma L.P. et al.	1:18-cv-10010	District of Massachusetts
Richland County Children's Services v. Purdue Pharma et al.	2017-cv-662; (removed 10/16/2017 to 1:17-cv-02185)	Northern District of Ohio (originally Court of Richland County)

Case Name	Case Number	Where Case Was Filed
Rockingham County v. AmerisourceBergen Drug Corporation et al.	1:17-cv-01114	Middle District of North Carolina
Ross County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00704	Southern District of Ohio
Rush Health Systems, Inc. v. McKesson Corp., et al.	3:17-cv-01012	Southern District of Mississippi
Scioto County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00682	Southern District of Ohio
Sheet Metal Workers Local No. 25 Health and Welfare Fund, on behalf of itself and all others similarly situated v. Purdue Pharma, LP et al.	2:17-cv-05079	Eastern District of Pennsylvania
Shelby County, by the Shelby County Board of Commissioners v. Purdue Pharma, LP et al.	CT-004500-17	Circuit Court for Shelby County, Tennessee
Southwest Mississippi Regional Medical Center; Infirmary Health Hospitals, Inc.; Monroe County Healthcare Authority d/b/a Monroe County Hospital, on behalf of themselves and all others similarly situated v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00145	Southern District of Mississippi
St. Bernard Parish Government versus Purdue Pharma L.P. et al.	17-1532	34th Judicial District Court for the Parish of St. Bernard
St. Croix Chippewa Indians v. McKesson Corporation et al.	3:17-cv-00914	Western District of Wisconsin
State of California v. Purdue Pharma LP,	30-2014-00725287-CU-BT-CXC	Orange County Superior Court

Case Name	Case Number	Where Case Was Filed
State of Mississippi v. Purdue Pharma et al.	G-2015-1814	Hinds County Chancery Court
State of New Mexico, ex rel. Hector Balderas, Attorney General v. Purdue Pharma LP et al.	D-101-CV-201702541	First Judicial District Court, County of Santa Fe, NM
State of Ohio v. Purdue Pharma	17CI000261	Ross County Court of Common Pleas
Sunflower County, Mississippi v Purdue Pharma L.P. et al.	4:17-cv-00189	Northern District of Mississippi
Surry County v. AmerisourceBergen Drug Corp. et. a.	1:17-cv-01159	Middle District of North Carolina
Tallapoosa County, Alabama v. AmerisourceBergen Drug Corporation et al.	3:17-cv-00763 17-op-45097 (MDL)	Middle District of Alabama
Teamsters Health Services and Insurance Plan Local 404, on behalf of itself and all others similarly situated v. Purdue Pharma LP, et al.	1:17-cv-12342	District of Massachusetts
The Borough of Ridgefield v. Purdue Pharma, L.P. et al.	BER-L-007640-17	Superior Court of New Jersey
The City of Columbus v. Purdue Pharma, L.P. et al.	2:17-cv-01102	Southern District of Ohio
The City of Elyria v. Purdue Pharma, LP et al.	17-CV-193904	Lorain County Court of Common Pleas
The City of Nashua v. Purdue Pharma L.P. et al.	1:17-cv-00730	District of New Hampshire

Case Name	Case Number	Where Case Was Filed
The City of Toledo v. Purdue Pharma, LP, et al.	3:17-cv-02516	Northern District of Ohio
The County of Ashtabula v. Purdue Pharma, L.P. et al.	2017-cv-0821	Ashtabula Court of Common Pleas, Ohio
The County of Clinton v. Purdue Pharma L.P. et al.	2018-00000052	Supreme Court of the State of NY County of Clinton
The County of Cuyahoga v. Purdue Pharma, LP., et al.	CV-17-888099	Cuyahoga Court of Common Pleas
The County of Floyd v. Purdue Pharma LP et al.	17-CI-00797	Circuit Court of Floyd County
The County of Jefferson v. Purdue Pharma L.P. et al.	17-CV-554	Court of Common Pleas, Jefferson County, Ohio
The County of Jefferson v. Purdue Pharma L.P. et al.	2:18-cv-00037-ALM-CMV	Southern District of Ohio
The County of Knott v. Purdue Pharma L.P. et al.	17-CI-00257	Circuit Court of Knott County, State of Kentucky
The County of Knott v. Purdue Pharma L.P. et al.	7:18-cv-00006-GFVT	Eastern District of Kentucky
The County of Lake v. Purdue Pharma L.P. et al.	17CV001972	Court of Common Pleas, Lake County, Ohio
The County of Lorain v. Purdue Pharma L.P. et al.	1:18-cv-00145	Northern District of Ohio

Case Name	Case Number	Where Case Was Filed
The County of Rensselaer v. Purdue Pharma, LP et al.	00257543 (Until a judge is assigned)	Rensselaer County Supreme Court
The County of Schoharie v. Purdue Pharma, LP et al.	2017-395	Schoharie County Supreme Court
The County of Tompkins v. Purdue Pharma L.P. et al.	EF2018-0008	Supreme Court of the State of NY County of Tompkins
The County of Trumbull v. Purdue Pharma L.P. et al.	4:18-cv-00147	Northern District of Ohio
The County of Trumbull v. Purdue Pharma L.P. et al.	2017 CV 02266	Court of Common Pleas, Trumbull County, Ohio
The Fiscal Court of Rowan County, on behalf of Rowan County v. AmerisourceBergen Drug Corp. et al.	0:17-cv-00130	Eastern District of Kentucky
The Fiscal Court of Allen County, on behalf of Allen County v. AmerisourceBergen Drug Corp. et al.	1:17-cv-00196	Western District of Kentucky
The Fiscal Court of Anderson County, on behalf of Anderson County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00070	Eastern District of Kentucky
The Fiscal Court of Bell County, on behalf of Bell County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00246	Eastern District of Kentucky
The Fiscal Court of Boone County, on behalf of Boone County v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00157	Eastern District of Kentucky
The Fiscal Court of Boyd County, on behalf of Boyd County v. AmerisourceBergen Drug Corp. et al.	0:17-cv-00104	Eastern District of Kentucky

Case Name	Case Number	Where Case Was Filed
The Fiscal Court of Boyle County, on behalf of Boyle County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00367	Eastern District of Kentucky
The Fiscal Court of Bullitt County, on behalf of Bullitt County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00727	Western District of Kentucky
The Fiscal Court of Campbell County, on behalf of Campbell County v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00167	Eastern District of Kentucky
The Fiscal Court of Carlisle County, on behalf of Carlisle County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00136	Eastern District of Kentucky
The Fiscal Court of Christian County, on behalf of Christian County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00146	Eastern District of Kentucky
The Fiscal Court of Clark County, on behalf of Clark County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00473	Eastern District of Kentucky
The Fiscal Court of Clay County, on behalf of Clay County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00255	Eastern District of Kentucky
The Fiscal Court of Cumberland County, on behalf of Cumberland County v. AmerisourceBergen Drug Corp. et al.	1:17-cv-00163	Eastern District of Kentucky
The Fiscal Court of Fleming County, on behalf of Fleming County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00368	Eastern District of Kentucky
The Fiscal Court of Franklin County, on behalf of Franklin County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00071	Eastern District of Kentucky

Case Name	Case Number	Where Case Was Filed
The Fiscal Court of Garrard County, on behalf of Garrard County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00369	Eastern District of Kentucky
The Fiscal Court of Greenup County, on behalf of Greenup County v. AmerisourceBergen Drug Corp. et al.	0:17-cv-00105	Eastern District of Kentucky
The Fiscal Court of Harlan County, on behalf of Harlan County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00247	Eastern District of Kentucky
The Fiscal Court of Henderson County, on behalf of Henderson County v. AmerisourceBergen Drug Corp. et al.	4:17-cv-00130	Western District of Kentucky
The Fiscal Court of Henry County, on behalf of Henry County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00073	Eastern District of Kentucky
The Fiscal Court of Hopkins County, on behalf of Hopkins County v. AmerisourceBergen Drug Corp. et al.	4:17-cv-00157	Western District of Kentucky
The Fiscal Court of Jessamine County, on behalf of Jessamine County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00438	Eastern District of Kentucky
The Fiscal Court of Kenton County, On Behalf Of Kenton County v. AmerisourceBergen Drug Corporation et al.	2:17-cv-00182	Eastern District of Kentucky
The Fiscal Court of Knox County, on behalf of Knox County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00248	Eastern District of Kentucky
The Fiscal Court of Laurel County, on behalf of Laurel County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00269	Eastern District of Kentucky

Case Name	Case Number	Where Case Was Filed
The Fiscal Court of Leslie County, on behalf of Leslie County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00249	Eastern District of Kentucky
The Fiscal Court of Lincoln County, on behalf of Lincoln County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00370	Eastern District of Kentucky
The Fiscal Court of Madison County, on behalf of Madison County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00371	Eastern District of Kentucky
The Fiscal Court of Marshall County, on behalf of Marshall County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00147	Western District of Kentucky
The Fiscal Court of Nicholas County, on behalf of Nicholas County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00373	Eastern District of Kentucky
The Fiscal Court of Oldham County, on behalf of Oldham County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00590	Western District of Kentucky
The Fiscal Court of Pendleton County, on behalf of Pendleton County v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00161	Eastern District of Kentucky
The Fiscal Court of Perry County, on behalf of Perry County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00265	Eastern District of Kentucky
The Fiscal Court of Pulaski County, on behalf of Pulaski County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00264	Eastern District of Kentucky
The Fiscal Court of Scott County, on behalf of Scott County v. AmerisourceBergen Drug Corp. et al.	5:17-cv-00474	Eastern District of Kentucky

Case Name	Case Number	Where Case Was Filed
The Fiscal Court of Shelby County, on behalf of Shelby County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00072	Eastern District of Kentucky
The Fiscal Court of Spencer County, on behalf of Spencer County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00557	Eastern District of Kentucky
The Fiscal Court of Union County, on behalf of Union County v. AmerisourceBergen Drug Corp. et al.	4:17-cv-00120	Western District of Kentucky
The Fiscal Court of Whitley County, on behalf of Whitley County v. AmerisourceBergen Drug Corp. et al.	6:17-cv-00250	Eastern District of Kentucky
The Fiscal Court of Woodford County, on behalf of Woodford County v. AmerisourceBergen Drug Corp. et al.	3:17-cv-00727	Eastern District of Kentucky
The Leech Lake Band of Ojibwe v Purdue Pharma L.P. et al.	0:17-cv-05491	District of Minnesota
The People of Northampton County and Northampton County, Pennsylvania v. Purdue Pharma L.P. et al.	C48-cv-2017-11557	Court of Common Pleas of Northampton County, Pennsylvania
The People of the County of Jersey v. Purdue	2017 L 000011 D 001	Jersey County Circuit Court
The People of the County of Union v. Purdue	2017 L 17	Jersey County Circuit Court (Consolidated) - 9/29/2017
The People of the State of Illinois, The People of Bond County, and County of Bond v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01170 18-op-45004 (MDL)	Southern District of Illinois

Case Name	Case Number	Where Case Was Filed
The People of the State of Illinois, The People of Christian County, and County of Christian v. AmerisourceBergen Drug Corporation et al	17-cv-3262 17-op-45078 (MDL)	Southern District of Illinois
The People of the State of Illinois, The People of Coles County, and County of Coles v. AmerisourceBergen Drug Corporation et al.	1:18-cv-01022-JBM-JEH	Central District of Illinois
The People of The State of Illinois, The People of Edwards County, and The County of Edwards v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01340 18-op-45049 (MDL)	Southern District of Illinois
The People of the State of Illinois, The People of Gallatin County, and County of Gallatin v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01171 17-op-45152 (MDL)	Southern District of Illinois
The People of the State of Illinois, The People of Hamilton County, and County of Hamilton v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01185 17-op-45157 (MDL)	Southern District of Illinois
The People of the State of Illinois, The People of Hardin County, and County of Hardin v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01172 18-op-45003 (MDL)	Southern District of Illinois
The People of The State of Illinois, The People of Jasper County, and The County of Jasper v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01342 18-op-45026 (MDL)	Southern District of Illinois
The People of the State of Illinois, The People of Pulaski County, and County of Pulaski v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01255 17-op-45158 (MDL)	Southern District of Illinois
The People of The State of Illinois, The People of Shelby County, and The County of Shelby v. AmerisourceBergen Drug Corporation et al.	3:17-cv-03293 18-op-45007 (MDL)	Central District of Illinois
The People of the State of Illinois, The People of Wabash County, and County of Wabash v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01173 17-op-45103 (MDL)	Southern District of Illinois

Case Name	Case Number	Where Case Was Filed
The People of the State of Illinois, The People of Washington County, and Washington County v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01174 17-op-45151 (MDL)	Southern District of Illinois
The People of The State of Illinois, The People of White County, and The County of White v. AmerisourceBergen Drug Corporation et al.	3:17-cv-01338 18-op-45024 (MDL)	Southern District of Illinois
The Town of Sheridan v. AmerisourceBergen Drug Corp. et al.	1:17-cv-04651 18-op-45055 (MDL)	Southern District of Indiana
The Township of Bloomfield, New Jersey v. Purdue Pharma L.P. et al.	2:17-cv-13462	District of New Jersey
Tippah County, Mississippi v. AmerisourceBergen Drug Corporation et al.	3:18-cv-00006-MPM- RP	Northern District of Mississippi
Township of Irvington v. Purdue Pharma LP et al.	2:17-cv-12155	District of New Jersey
Transferred to NY-Suffolk Supreme Court (formerly The County of Nassau v. Purdue)	400000/2017 (Nassau is 40008/2017)	Suffolk County Supreme Court
Union County, Mississippi v. AmerisourceBergen Drug Corporation et al.	3:18-cv-00008-SA- JMV	Northern District of Mississippi
United Food and Commercial Workers Health and Welfare Fund of Northeastern Pennsylvania, on behalf of itself and all others similarly situated v. Purdue Pharma, LP et al.	2:17-cv-05078	Eastern District of Pennsylvania
Vigo County, Indiana v. AmerisourceBergen Drug Corporation et al.	2:18-cv-00010	Southern District of Indiana

Case Name	Case Number	Where Case Was Filed
Vinton County Board of County Commissioners v. AmerisourceBergen Drug Corp. et al.	2:17-cv-00665	Southern District of Ohio
Washington County v. Purdue Pharma LP et al.	0:17-cv-05287	District of Minnesota
Washington County, Mississippi v. Purdue Pharma, LP et al.	4:17-cv-00191	Northern District of Mississippi
Williamson County, Tennessee v. AmerisourceBergen Drug Corporation et al.	3:18-cv-00008	Middle District of Tennessee
Yadkin County v. AmerisourceBergen Drug Corp., et al.	1:17-cv-01085	Middle District of North Carolina